Singapore, Aug. 22 -- China'sBioDlinkhasannounced that its Bevacizumab Injection has obtained marketing authorisation fromIndonesia'sNational Agency of Drug and Food Control (BPOM). This marks BioDlink's fourth international approval within two months - followingNigeria,Pakistan, andColombia- signaling accelerated BioDlink's global expansion into a sustained commercialisation phase.

Indonesia, the world's fourth-most populous nation, reports over 400,000 new cancer cases annually (WHO). Yet biologics accessibility remains below 15%. As ASEAN's largest pharmaceutical market and regulatory hub, this approval expedites regional market access acrossSoutheast Asia. BioDlink's cost-effective bevacizumab, manufactured inChinain compliance with ...